第 1 到 97 筆結果,共 97 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | Reply | SHANG-CHIN HUANG ; TUNG-HUNG SU ; JIA-HORNG KAO | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | |||
2 | 2024 | Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy” | Lin, Meng-Ju; TUNG-HUNG SU ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
3 | 2023 | Hepatitis D Virus Infection | SHANG-CHIN HUANG ; JIA-HORNG KAO | The New England journal of medicine | |||
4 | 2023 | Gamma-glutamyl transferase levels in the prediction of the outcomes of hepatocellular carcinoma after surgical resection | TUNG-HUNG SU ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
5 | 2023 | Reply | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
6 | 2023 | Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B | SHANG-CHIN HUANG ; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 1 | 1 | |
7 | 2023 | Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B | Huang, Chiuan-Bo; TUNG-HUNG SU ; JIA-HORNG KAO | Liver international : official journal of the International Association for the Study of the Liver | 1 | 1 | |
8 | 2022 | Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities | Hsu, Yao-Chun; Tseng, Cheng-Hao; TUNG-HUNG SU ; JIA-HORNG KAO ; Nguyen, Mindie H | Gut | 3 | 2 | |
9 | 2022 | Global multi-stakeholder endorsement of the MAFLD definition | Méndez-Sánchez, Nahum; Bugianesi, Elisabetta; Gish, Robert G; Lammert, Frank; Tilg, Herbert; Nguyen, Mindie H; Sarin, Shiv K; Fabrellas, Núria; Zelber-Sagi, Shira; Fan, Jian-Gao; Shiha, Gamal; Targher, Giovanni; Zheng, Ming-Hua; Chan, Wah-Kheong; Vinker, Shlomo; Kawaguchi, Takumi; Castera, Laurent; Yilmaz, Yusuf; Korenjak, Marko; Spearman, C Wendy; Ungan, Mehmet; Palmer, Melissa; El-Shabrawi, Mortada; Gruss, Hans-Juergen; Dufour, Jean-François; Dhawan, Anil; Wedemeyer, Heiner; George, Jacob; Valenti, Luca; Fouad, Yasser; Romero-Gomez, Manuel; Eslam, Mohammed; JIA-HORNG KAO et al. | The lancet. Gastroenterology & hepatology | 139 | 123 | |
10 | 2022 | Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria" | CHIH-HORNG WU ; JIA-HORNG KAO | Hepatology international | 0 | 0 | |
11 | 2022 | Letter to the editor: New kid in the playground: HBcrAg and risk of HCC | Wu J.-W.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
12 | 2022 | Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum | SHANG-CHIN HUANG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 2 | 2 | |
13 | 2022 | Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry | Wong Y.J.; Kumar R.; Kumar R.; Tan J.; CHEN-HUA LIU ; Hui V.W.-K.; Tan S.S.; JIA-HORNG KAO ; Wong G.L.-H.; Thurairajah P.H. | Journal of Gastroenterology and Hepatology (Australia) | 4 | 2 | |
14 | 2021 | Response to letter to the editor “Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy” | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
15 | 2021 | Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection—authors' reply | TAI-CHUNG TSENG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
16 | 2021 | Reply to: “Sofosbuvir and the risk of kidney dysfunction” | CHEN-HUA LIU ; JIA-HORNG KAO | Journal of Hepatology | 0 | 0 | |
17 | 2021 | Reply to “Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia” | Yu M.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
18 | 2021 | Response to letter to the editor “The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma” | Cheng Y.-M.; Tzeng I.-S.; JIA-HORNG KAO ; Wang C.-C. | Journal of the Formosan Medical Association | 0 | 0 | |
19 | 2020 | Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply | Wai-Sun Wong V.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
20 | 2020 | letter: hepatitis B virus infection and risk of multiple myeloma—a meta-analysis of cohort studies. Authors' reply | TUNG-HUNG SU ; CHI-LING CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
21 | 2020 | Reply to letter to the editor: Successful eradication of HCV by short-course DAAs in HCV positive donor to HCV-Negative recipient during Haplo-HSCT | Huang C.-F.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
22 | 2019 | The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? | Wang C.-C.; JIA-HORNG KAO | Hepatology | 2 | 1 | |
23 | 2019 | Large and middle hepatitis B surface antigen: The lower the better? | Lin H.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Gut | 1 | 1 | |
24 | 2019 | Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
25 | 2019 | Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus | HUNG-CHIH YANG ; JIA-HORNG KAO | Gut | 4 | 2 | |
26 | 2019 | Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done | Hsu Y.-C.; Tseng C.-H.; JIA-HORNG KAO | Clinical Gastroenterology and Hepatology | 5 | 2 | |
27 | 2018 | HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed? | TUNG-HUNG SU ; TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 11 | 10 | |
28 | 2017 | Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation | Wang C.-C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
29 | 2017 | Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; JIA-HORNG KAO | Liver International | 2 | 2 | |
30 | 2017 | Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir | CHEN-HUA LIU ; YIH-SHARNG CHEN ; SHOEI-SHEN WANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 4 | 6 | |
31 | 2017 | letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D | Kao C.-N.; TUNG-HUNG SU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
32 | 2017 | Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study | Wang C.-C.; JIA-HORNG KAO | Hepatology | 14 | 12 | |
33 | 2017 | More viral mutants, less HBsAg clearance? One size may not fit all | TAI-CHUNG TSENG ; HUNG-CHIH YANG ; JIA-HORNG KAO | Gut | 2 | 1 | |
34 | 2017 | HBV markers for HCC prediction: Three heads are better than two? | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Hepatology | 6 | 3 | |
35 | 2016 | Reply | Su T.-H.; CHI-LING CHEN ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
36 | 2015 | Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients | YI-WEN HUANG ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 0 | 0 | |
37 | 2015 | Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B? | Lin C.-L.; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 1 | 1 | |
38 | 2014 | Triple therapy for hepatitis C virus infection in patients receiving hemodialysis | CHEN-HUA LIU ; JIA-HORNG KAO | Annals of Internal Medicine | 1 | 1 | |
39 | 2013 | Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients | Yuan Q.; Song L.-W.; CHUN-JEN LIU ; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; JIA-HORNG KAO ; DING-SHINN CHEN ; PEI-JER CHEN ; Xia N.-S. | Gut | 67 | 63 | |
40 | 2012 | Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg? | TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
41 | 2011 | Alpha-fetoprotein in chronic hepatitis C | Hsu C.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
42 | 2011 | Hepatitis during antituberculosis treatment | Wu L.-W.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
43 | 2011 | Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling | Hsu C.-S.; Chen H.-C.; Jeng J.; JIA-HORNG KAO ; DING-SHINN CHEN | Proceedings of the National Academy of Sciences of the United States of America | 0 | 0 | |
44 | 2011 | Uncovered issues in the overview of nonalcoholic steatohepatitis | Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
45 | 2010 | Metabolic syndrome on top of chronic hepatitis B: the more, the worse? | LI-CHUN CHANG ; Chung, Chen-Shuan; CHUN-JEN LIU ; JIA-HORNG KAO | Gut | 1 | 1 | |
46 | 2010 | Role of Viral Factors in Modifying Weight-Related Effects on Disease Progression of Chronic Hepatitis C Patients | Hsu C.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
47 | 2010 | From liver markers to life expectancy | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
48 | 2010 | Letter to the editor | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 2 | ||
49 | 2010 | Use of statins and gallstone risk [1] | Hsu C.-S.; JIA-HORNG KAO | JAMA - Journal of the American Medical Association | 4 | 3 | |
50 | 2010 | Rifaximin treatment in hepatic encephalopathy [1] | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 13 | 5 | |
51 | 2010 | Alanine aminotransferase, metabolic syndrome, and cardiovascular disease: A missing link | Wang C.-C.; JIA-HORNG KAO | American Journal of Gastroenterology | 3 | 2 | |
52 | 2010 | Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box | Wang C.-C.; JIA-HORNG KAO | Hepatology | 4 | 5 | |
53 | 2010 | Metformin improves sustained virologic response in difficult-to-cure hepatitis c: More questions than answers | Wang C.-C.; JIA-HORNG KAO | Hepatology | 3 | 3 | |
54 | 2010 | Carvedilol versus variceal band ligation for prevention of the first variceal bleed | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
55 | 2009 | HBV genotypes and chronicification of acute hepatitis B: More questions than answers | Lin C.-L.; JIA-HORNG KAO | Gut | 1 | 0 | |
56 | 2009 | Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease | Hsu C.-S.; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
57 | 2009 | Capsule endoscopy versus colonoscopy | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 0 | ||
58 | 2009 | Telaprevir for chronic HCV infection | JIA-HORNG KAO | New England Journal of Medicine | 3 | 3 | |
59 | 2009 | Esomeprazole for asthma [7] | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 1 | 2 | |
60 | 2009 | HBsAg Seroclearance: The More and Earlier, the Better | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 4 | 4 | |
61 | 2009 | Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy | TAI-CHUNG TSENG ; CHUN-JEN LIU ; SONG-CHOU HSIEH ; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN ; JIA-HORNG KAO | Digestive and Liver Disease | 3 | 3 | |
62 | 2009 | Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 4 | 2 | |
63 | 2009 | Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; Tsai H.-B.; Hung P.-H.; SHIH-JER HSU ; Chen S.-L.; JOU-WEI LIN ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gut | 26 | 23 | |
64 | 2008 | Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link? | Hsu C.-S.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
65 | 2008 | Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection | TUNG-HUNG SU ; CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | American Journal of Gastroenterology | 0 | 0 | |
66 | 2008 | Combination of Hepatitis B Viral Factors and Advanced Liver Disease in HBeAg-Negative Patients: The More, the Worse? | Lin C.; Branch R.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
67 | 2008 | HBV Genotype and Clinical Outcome of Chronic Hepatitis B: Facts and Puzzles | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 17 | 16 | |
68 | 2007 | Reply [2] | Lin C.-L.; CHUN-JEN LIU ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
69 | 2007 | Viremia profiles in hepatitis B virus carrier children with spontaneous e antigen seroconversion: a case of déjà vu? | Lin C.-L.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
70 | 2007 | Intrafamilial transmission of hepatitis B virus infection [3] | Lin C.-L.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 3 | 2 | |
71 | 2007 | To genotype or not to genotype: Toward an optimal tailoring of treatment of chronic hepatitis B [3] | Lin C.-.; JIA-HORNG KAO | Clinical Infectious Diseases | 2 | 3 | |
72 | 2007 | Sequential combination therapy for chronic hepatitis B: More challenges to be tackled [7] | TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | American Journal of Gastroenterology | 1 | 1 | |
73 | 2007 | APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5] | TUNG-HUNG SU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 0 | 0 | |
74 | 2007 | Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV [6] | CHEN-HUA LIU ; DING-SHINN CHEN ; JIA-HORNG KAO | New England Journal of Medicine | 1 | 1 | |
75 | 2007 | Hypercholesterolemia in primary biliary cirrhosis [10] | TA-CHEN SU ; HWANG, JUEY-JEN ; JIA-HORNG KAO | New England Journal of Medicine | 20 | 20 | |
76 | 2006 | Mixed hepatitis B virus genotype infections: The more, the worse? [3] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 8 | 5 | |
77 | 2006 | Local ablation vs. resection for the treatment of hepatocellular carcinoma [1] | JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 5 | 4 | |
78 | 2006 | Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Gastroenterology | 7 | 7 | |
79 | 2006 | Clinical significance of occult hepatitis B virus infection cannot be overlooked [11] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Clinical Infectious Diseases | 1 | 1 | |
80 | 2005 | Effects of diabetes on the ED presentation of acute intermittent porphyria [3] | Chen H.-W.; Su D.-H.; TZUU-SHUH JOU ; JIA-HORNG KAO | American Journal of Emergency Medicine | 0 | 0 | |
81 | 2005 | Subgenotypes of hepatitis B virus genotype C in Taiwan [3] (multiple letters) | CHUN-JEN LIU ; JIA-HORNG KAO ; Chan H.L.-Y. | Journal of Infectious Diseases | 4 | 4 | |
82 | 2005 | HBV genotypes and outcome of HBV infection [1] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Lok A.S.F. | Hepatology | 7 | 6 | |
83 | 2005 | Medical treatment of fish bone-related liver abscess [5] | Yang C.-Y.; JIA-HORNG KAO ; KAO-LANG LIU ; SHYH-JYE CHEN | Clinical Infectious Diseases | 15 | 12 | |
84 | 2004 | Heterogeneity of hereditary persistence of alpha-fetoprotein [1] (multiple letters) | Shiou-Hwei Yeh ; JIA-HORNG KAO ; PEI-JER CHEN ; Perlemuter G.; Alj Y.; Buffet C.; Guiochon-Mantel A. | Gastroenterology | 0 | 5 | |
85 | 2004 | Hepatitis B Virus Genotypes and Core Promoter Variant [10] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Lok A.S.F. | Gastroenterology | 0 | 1 | |
86 | 2003 | Molecular Assays for Hepatitis B Virus Infection [1] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 5 | 5 | |
87 | 2003 | Clinical Relevance of Hepatitis B Virus Genotypes Ba and Bj in Taiwan [6] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Sugauchi F.; Miyakawa Y.; Mizokami M. | Gastroenterology | 18 | 14 | |
88 | 2002 | Paratyphoid hepatitis: An emerging clinical entity [5] | PO-REN HSUEH ; JIA-HORNG KAO ; YEE-CHUN CHEN ; PAN-CHYR YANG ; KWEN-TAY LUH ; Wang T.-K.; Lin S.-F. | American Journal of Medicine | 7 | 5 | |
89 | 2002 | Hepatitis B viral genotypes and lamivudine resistance [1] | JIA-HORNG KAO ; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Hepatology | 101 | 84 | |
90 | 2001 | Mother-to-child HCV transmission [1] (multiple letters) | Semprini A.E.; Savasi V.; Hollander L.; Tanzi E.; Fiore S.; Newell M.-L.; Pembrey L.; Zanetti A.; Coll O.; Numazaki K.; Fujikawa T.; Chiba S.; Hari P.; Prasad C.G.K.; Lankipalli R.; HO-HSIUNG LIN ; JIA-HORNG KAO ; DING-SHINN CHEN ; Gibb D.M.; Dunn D.T.; Goodall R.L. | Lancet | 7 | 3 | |
91 | 1998 | Hepatitis C virus infection and chronic active myocarditis [3] (multiple letters) | JIA-HORNG KAO ; HWANG, JUEY-JEN ; Okabe M.; Fukuda K.; Arakawa K.; Kikuchi M. | Circulation | 2 | 2 | |
92 | 1997 | Blood-bank screening for hepatitis G [14] | JIA-HORNG KAO ; PEI-JER CHEN ; JIN-TOWN WANG ; Lai M.-Y.; DING-SHINN CHEN | Lancet | 7 | 5 | |
93 | 1996 | Mechanism of vertical transmission of hepatitis G [6] | HO-HSIUNG LIN ; IA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | Lancet | 40 | 27 | |
94 | 1996 | GBV-C in the aetiology of fulminant hepatitis [6] | JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN ; Mishiro S.; Yoshiba M.; Okamoto H. | Lancet | 83 | 87 | |
95 | 1996 | GBV-C/HGV infection and aplastic anaemia [7] | JIA-HORNG KAO ; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN | Lancet | 9 | 8 | |
96 | 1995 | Reply To the Editor | Lin H.-H.; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | The Journal of Pediatrics | 0 | 0 | |
97 | 1993 | Sexual transmission of HCV | JIA-HORNG KAO ; PEI-JER CHEN ; Lei M.-Y.; Wang T.-H.; Chen D.-S.; Benezra J. | The Lancet | 11 | 15 |